Chest
Volume 124, Issue 4, Supplement, January 2003, Page 182S
Journal home page for Chest

Cost-effectiveness of Linezolid for Treatment of Ventilator-Associated Pneumoni

https://doi.org/10.1378/chest.124.1.275Get rights and content

Section snippets

Abstract

PURPOSE: Our goals were to determine the incremental cost-effectiveness of linezolid (LIN) compared to vancomycin (VAN) for VAP due to S. aureus and to investigate the cost-effectiveness of broader use of bronchoscopy (FOB) in the management of VAP.

METHODS: We modeled the cost and efficacy of LIN vs. VAN for treatment of VAP. The primary outcome was the incremental cost-effectiveness of LIN in terms of cost per added quality-adjusted life-year (QALY) gained. A second model investigated the

References (0)

Cited by (59)

View all citing articles on Scopus
View full text